OptiBiotix Health PLC License agreement for LPLDL® (4420Z)
20 May 2019 - 4:00PM
UK Regulatory
TIDMOPTI
RNS Number : 4420Z
OptiBiotix Health PLC
20 May 2019
OptiBiotix Health plc
("OptiBiotix" or the "Company")
LP(LDL) (R) license agreement for new application in
hypertension
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, cardiovascular disease and
diabetes, announces that its fully-owned subsidiary ProBiotix
Health Ltd. ("ProBiotix"), has signed a license agreement with
Nutrilinea Srl. ("Nutrilinea") for the use of LP(LDL) (R) in a food
supplement for the reduction of high blood pressure (hypertension).
Nutrilinea will cover the cost of all product development,
manufacturing and human studies in return for 12 months exclusivity
for the European market. ProBiotix has exclusivity for the UK and
all other markets outside Europe.
Nutrilinea, based near Milan in northern Italy, is a
manufacturer of food supplement formulations containing probiotics,
with over 15 years' experience in the development of products for
the food and pharmaceutical industries in Europe and the United
States. It is one of OptiBiotix's preferred manufacturers, and
currently produces the Company's CholBiome(R), CholBiome(R)(x3) and
SlimBiome(R) Medical products. Nutrilinea has technology that
enables the production of multilayer tablets used in
CholBiome(R)(x3) which will also be used for this new product. In
an independent human study by the University of Reading, there was
a statistically significant reduction in both blood pressure and
cholesterol in volunteers taking LP(LDL) (R) compared to a control
group (Costabile et al., 2017). The European Cardiovascular Society
reported in 2016 that the combination of lowering LDL cholesterol
and systolic blood pressure has the potential to "dramatically
reduce" a person's lifetime risk of cardiovascular disease.
Hypertension is a global healthcare issue and is one of the
strongest risk factors for almost all cardiovascular diseases. The
fact that it does not have obvious symptoms have lead doctors to
call hypertension a 'silent killer'. Studies conducted in Europe
and in the United States suggest that, under new hypertension
guidelines, a large percentage of the adult population may be
considered hypertensive: some 14 million people in the UK and over
100 million in the US.
https://www.independent.co.uk/news/health/adults-heart-attacks-strokes-early-death-high-blood-pressure-pills-a8247051.html
https://www.heart.org/en/news/2018/05/01/more-than-100-million-americans-have-high-blood-pressure-aha-says
Dr Luis Gosalbez, Business Development Director of OptiBiotix,
commented: "We are delighted to announce this deal with Nutrilinea
who are covering the cost of product development, manufacturing and
human studies, for a food supplement to reduce blood pressure. This
broadens the use of LP(LDL) (R) beyond cholesterol reduction and
creates new market opportunities in the field of cardiovascular
health. Hypertension is a global health issue which is on the rise
where there are very few active ingredients or supplements proven
to lower blood pressure in humans. The development of a
hypertension product containing LP(LDL) (R) has the potential to
address a large global market of unmet clinical need."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner Tel: 020 7213 0880
finnCap (Broker)
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking) Tel: 020 7220 0500
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRLDLFFKEFBBBF
(END) Dow Jones Newswires
May 20, 2019 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024